One more completed stock market debut and 2021 will have officially matched last year with the highest number of biopharma IPOs on record, and amounts collected through venture capital financings have now risen to the top as well.

Total raised in public, private and other financings of biopharma companies, comparing 2021 vs. 2020 vs. 2019.

Year-to-date money raised in public, private and other financings of biopharma companies.

These graphs compare the performance of the biotech stocks for all of 2021 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.

While the volume of regulatory data is above this point last year by more than 17%, the proportion of COVID-19-related news is nearly the same, as is the number of U.S.-approved new molecular entities (NMEs).

The top 10 med-tech stock gainers and losers for the week.